The Clinical Challenge

Individuals at risk for colon cancer often go undetected until it’s too late. Colorectal cancer is the second leading cause of cancer deaths in the United States, affecting over 150,000 individuals annually. Many diagnosed patients have no family history or identifiable risk factors.

While colonoscopy is the reliable standard, it remains underutilized due to practical and personal barriers. Research shows that more than half of those who should get screened, don’t.

Our Diagnostic Approach

A non-invasive test could greatly simplify the screening process. Using a small probe inserted just inside the rectum, we envision a test easily administered by a physician to identify patients at high risk for cancer who are in need of additional follow-up.

Development Pipeline

The research team at American BioOptics is committed to innovation. In collaboration with Northwestern University and Evanston Northwestern Healthcare, we have completed significant early clinical work.

Initial results show a high degree of sensitivity and specificity. Over the coming years, ABO will perform extensive clinical trials, leading to FDA submission and eventual commercialization.